Immix Biopharma Investor Presentation Deck
Potential to Disrupt the $230bn+ Oncology and Immunology Categories
2030 Market
Opportunity
Broad platforms driving next-generation
therapies in blood cancers, solid tumors and
immunology
MULTIPLE
MYELOMA
$29B+
CELL THERAPY
PD-1 ANNUAL
SALES -
KEYTRUDAⓇ +
OPDIVOⓇ
$29 B
SOLID TUMORS +
IMMUNOLOGY
AL
Amyloidosis
$4B+
CELL THERAPY
CELL THERAPY
Hematologic Malignancies
Acute lymphocytic leukemia
Large B-Cell Lymphoma
Mantle Cell Lymphoma
Acute Myeloid Leukemia
●●●
IMMIX
S BIOPHARMA
SOLID TUMORS +
IMMUNOLOGY
Soft Tissue Sarcoma
Colorectal Cancer
Inflammatory Bowel Disease
$175B+
Sources: Hematologic cancers market size source: reportsanddata.com. Merck Financial Results, 2022 Bristol Meyers Squibb Financial Results. AL Amyloidosis market size according to Grand View Research. Hematological Malignancies reportsanddata.com, ALL allied market research.com, LBCL
datamintelligence.com, MCL dataintelio.com, AML GlobalData, STS MedGadget, CRC Industry Arc, Prometheus Biosciences S-1.
29View entire presentation